Phase 2 Eczema Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older (as allowed by local rules) at the time of the screening visit
- People who have been diagnosed with atopic dermatitis (eczema), with symptoms that started at least 1 year before the screening visit
- People whose atopic dermatitis is considered moderate to severe at screening, based on specific skin assessment scores measured by a doctor (confirm with trial site for exact score details)
- People who have an average itch score of 4 or higher over the 7 days before the start of the trial
- People who have a documented history of using either a topical (applied to skin) or systemic (whole-body) treatment for their atopic dermatitis within the 6 months before joining the trial
- Women who are not pregnant or breastfeeding, and who are either unable to become pregnant, or who agree to use highly effective contraception during the trial
Who may not be able to join:
- People who have other skin conditions that could make it difficult to assess how the study treatment is affecting their atopic dermatitis
- People with other active skin diseases or skin infections (bacterial, fungal, or viral) that require treatment taken throughout the body, within 30 days before the baseline visit
- People with a known immune deficiency condition, a history of a serious internal infection, or a current non-skin infection requiring systemic anti-infective treatment within 30 days of the baseline visit
- People with a history of a weakened immune system not caused by medication, a significant medical history, or any other condition that the trial doctor believes would interfere with participation
- People with an unstable or poorly controlled illness, including heart, breathing, digestive, hormonal, blood, or neurological conditions that could affect safety or make it harder to assess the trial results
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Isin Sinem Bagci, MD, Corvus Pharmaceuticals, Inc.
Phone: 650-889-4390
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Percent change from baseline in Eczema Area and Severity Index (EASI) score at Week 12
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.